Who are TS-1's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Xeloda, Fudr, Folic Acid, Capecitabine (Xeloda®), Fluorouracil Injection, FLOX.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ts-1.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

TS-1 — Competitive Intelligence Brief

TS-1 (TS-1) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimetabolite chemotherapy combination. Area: Oncology.

phase 3 Antimetabolite chemotherapy combination Thymidylate synthase Oncology Small molecule Live · refreshed every 30 min

Target snapshot

TS-1 (TS-1) — National Health Research Institutes, Taiwan. TS-1 is an oral combination chemotherapy agent that inhibits thymidylate synthase and enhances fluorouracil activity against cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
TS-1 TARGET	TS-1	National Health Research Institutes, Taiwan	phase 3	Antimetabolite chemotherapy combination	Thymidylate synthase
Xeloda	capecitabine	Cheplapharm	marketed	Nucleoside Metabolic Inhibitor [EPC]	Thymidylate synthase	1998-01-01
Fudr	FLOXURIDINE		marketed	Antimetabolite [EPC]	Thymidylate synthase	1970-01-01
Folic Acid	FOLIC ACID	Pfizer	marketed	Vitamin C [EPC]	Thymidylate synthase	1946-01-01
Capecitabine (Xeloda®)	Capecitabine (Xeloda®)	National Cancer Center, Korea	marketed	Fluoropyrimidine antimetabolite	Thymidylate synthase
Fluorouracil Injection	Fluorouracil Injection	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	marketed	Antimetabolite	Thymidylate synthase
FLOX	FLOX	Hospira	marketed		Thymidylate synthase, Thymidylate synthase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimetabolite chemotherapy combination class)

Asan Medical Center · 1 drug in this class
Centre Hospitalier Universitaire de Besancon · 1 drug in this class
National Health Research Institutes, Taiwan · 1 drug in this class
Odense University Hospital · 1 drug in this class
Pfizer · 1 drug in this class
Shanghai Pulmonary Hospital, Shanghai, China · 1 drug in this class
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TS-1 — Competitive Intelligence Brief. https://druglandscape.com/ci/ts-1. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab